| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |